JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

82.34 -1.29

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

82.17

Max

83.82

Galvenie mērījumi
By Trading Economics
Ienākumi	-252M -129M
Pārdošana	-295M 157M
Peļņas marža	-82.062
Darbinieki	1,069
EBITDA	-254M -103M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+16.41% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 18. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.5B 13B
Iepriekšējā atvēršanas cena	83.63
Iepriekšējā slēgšanas cena	82.34

Ziņu noskaņojums

By Acuity

80%

20%

327 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. janv. 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

2026. g. 30. janv. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

2026. g. 30. janv. 23:41 UTC

Tirgus saruna

Deckers Outdoor Seen as Undervalued -- Market Talk

2026. g. 30. janv. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

2026. g. 30. janv. 22:20 UTC

Peļņas

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

2026. g. 30. janv. 22:10 UTC

Tirgus saruna

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

2026. g. 30. janv. 21:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 30. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 30. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 30. janv. 21:42 UTC

Peļņas

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

2026. g. 30. janv. 21:36 UTC

Peļņas

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

2026. g. 30. janv. 21:33 UTC

Peļņas

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

2026. g. 30. janv. 20:42 UTC

Peļņas

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

2026. g. 30. janv. 20:37 UTC

Iegādes, apvienošanās, pārņemšana

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

2026. g. 30. janv. 20:20 UTC

Tirgus saruna

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

2026. g. 30. janv. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

2026. g. 30. janv. 19:52 UTC

Peļņas

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

2026. g. 30. janv. 19:29 UTC

Tirgus saruna

Peļņas

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

2026. g. 30. janv. 19:09 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. janv. 19:09 UTC

Tirgus saruna

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

2026. g. 30. janv. 19:07 UTC

Tirgus saruna

Canada Performing Well Below Economic Potential -- Market Talk

2026. g. 30. janv. 18:46 UTC

Peļņas

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

2026. g. 30. janv. 18:34 UTC

Peļņas

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

16.41% augšup

Prognoze 12 mēnešiem

Vidējais 95.36 USD 16.41%

Augstākais 110 USD

Zemākais 77 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

327 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.